48-week efficacy and safety of transitioning virologically stable HIV-1 patients from nevirapine IR 200 mg BID to nevirapine XR 400 mg QD (TRANxITION)

por Arastéh, K, Ward, A, Plettenberg, A, Livrozet, JM, Cordes, C, Winston, A, Wang, E, Quinson, A
Publicado 2010

Switch from a ZDV/3TC-based regimen to a completely once daily (QD) regimen of emtricitabine/tenofovir DF fixed dose combination plus a third QD agent (SONETT)

por Arasteh, K, Weitner, L, Fenske, S, Kuhlmann, B, Freiwald, M, Ebrahimi, R, Gallo, L, Ranneberg, B, Mertenskoetter, T
Publicado 2009

Potential geographic "hotspots" for drug-injection related transmission of HIV and HCV and for initiation into injecting drug use in New York City, 2011-2015, with implications for...

por Des Jarlais, D. C., Cooper, H. L. F., Arasteh, K., Feelemyer, J., McKnight, C., Ross, Z.
Publicado 2018

Geographic distribution of risk (“Hotspots”) for HIV, HCV, and drug overdose among persons who use drugs in New York City: the importance of local history

por Des Jarlais, D.C., McKnight, C., Arasteh, K., Feelemyer, J., Ross, Zev, Cooper, H. L. F.
Publicado 2019

Treatment of HIV-related primary central nervous system lymphoma with azt high dose, HAART, interleukin-2 and foscarnet in three patients

por Marretta, L, Stocker, H, Drauz, D, Mueller, M, Masuhr, A, Dieckmann, S, Wong, V, Koch, A, Grueneisen, A, Arastéh, K, Weiss, R
Publicado 2011

Quality of T-cell responses versus reduction in viral load: results from an exploratory phase II clinical study of Vacc-4x, a therapeutic HIV vaccine

por Ellefsen-Lavoie, K, Rockstroh, J, Pollard, R, Pantaleo, G, Podzamczer, D, Asmuth, D, van Lunzen, J, Arastéh, K, Schürmann, D, Peters, B, Clotet, B, Hardy, D, Lazzarin, A, Gatell, J, Sommerfelt, MA, Baksaas, I, Wendel-Hansen, V, Sørensen, B
Publicado 2012